Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
Status:
Terminated
Trial end date:
2019-02-15
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and effectiveness of intranasal (IN) glulisine in patients
with amnestic mild cognitive impairment (aMCI) and probable Alzheimer's disease. Half of
participants will receive IN glulisine, while the other half will receive IN placebo.